Sharechat Logo

Flannagan to leave Tower after strategic review, asset sales

Thursday 21st March 2013

Text too small?

Rob Flannagan is to step down as managing director of Tower following the completion of the listed insurer's strategic review and sale of its health and investment units.

Flannagan will work out the 12 months of his notice, the company said in a statement. He has led Tower for seven years.

"Tower now has a refreshed board with a clear direction of where it wishes Tower to be in the future," he said. "It is time to step aside to allow a new leader to guide the company in its preferred direction."

Tower embarked on a review of what were then its four operating units in 2010 on the basis that its share price didn't reflect the value of the underlying businesses.

Fisher Funds acquired Tower Investments for $79 million last month to add to its KiwiSaver pool.

in a deal backed by new shareholder TSB Bank. It sold its medical insurance unit to Australia's nib in November for $102 million and plans to return $120 million to shareholders.

Tower shares rose 0.5 percent to $1.88 and have declined 3 percent this year. It is rated 'hold' based on the consensus in a Reuters survey of four analysts, with a median price target of $2.

BusinessDesk.co.nz

Father's Day SOON! Crazy Deals on ALL IRG Yearbooks - More than 50% OFF - $19.99 for 44th IRG Yearbook 2018-2019


  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Tower to return 'initial' $70M of capital from sale of life business
Tower shares fall to 2-month low as licensing requirements may weigh on capital returns
Tower's licensing talks with RBNZ may push up minimum solvency requirements
Tower names Hancock as new chief executive, replacing Flannagan
Tower posts first-half profit as asset sales reap gains of $51.4 mln
Fidelity Life acquires most of Tower's life insurance business
Tower FY profit jumps 67%, to return $120M to shareholders; shares jump
Tower sells medical insurance unit to nib for $102M
Stiassny joins Tower board as questions linger over strategy
Tower lifts premiums for house, contents and motor cover